NT_1170x120_1-11-18

Tom Hardy

Lilly presents new diabetes data at ADA session

Lilly presents new diabetes data at ADA session

ORLANDO, Fla. — Eli Lilly’s ultra rapid lispro (URLi) led to improved and sustained blood sugar control after meals in people with type 1 and type 2 diabetes, according to results from three phase 1b studies evaluating URLi compared to Humalog. URLi is Lilly’s novel mealtime insulin currently in phase 3 development. The data was presented in